Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
postremission therapy (30) 30
humans (27) 27
life sciences & biomedicine (24) 24
science & technology (24) 24
remission induction (20) 20
adult (19) 19
hematology (19) 19
middle aged (19) 19
female (17) 17
male (16) 16
oncology (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
acute myeloid leukemia (14) 14
adolescent (14) 14
leukemia, myeloid, acute - therapy (14) 14
biological and medical sciences (13) 13
medical sciences (13) 13
aged (12) 12
chemotherapy (12) 12
disease-free survival (11) 11
leukemia, myeloid, acute - mortality (11) 11
treatment outcome (11) 11
acute myelogenous leukemia (9) 9
pharmacology. drug treatments (9) 9
prognosis (9) 9
antineoplastic agents (8) 8
cytarabine - administration & dosage (8) 8
follow-up studies (8) 8
hematopoietic stem cell transplantation (8) 8
leukemia, myeloid, acute - genetics (8) 8
hematologic and hematopoietic diseases (7) 7
leukemia, myeloid, acute - drug therapy (7) 7
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (7) 7
aml (6) 6
stem cells (6) 6
survival analysis (6) 6
survival rate (6) 6
acute disease (5) 5
colony-stimulating factor (5) 5
hematopoietic stem cell transplantation - methods (5) 5
leukemia, myeloid, acute - pathology (5) 5
retrospective studies (5) 5
transplantation (5) 5
transplantation, homologous (5) 5
umcg approved (5) 5
adults (4) 4
bone-marrow-transplantation (4) 4
cancer (4) 4
hematopoietic stem cells (4) 4
leukemia (4) 4
medicine & public health (4) 4
mutation (4) 4
time factors (4) 4
transplantation, autologous (4) 4
acute lymphoblastic leukemia (3) 3
age factors (3) 3
allogeneic stem cell transplantation (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bone marrow transplantation (3) 3
cytarabine - therapeutic use (3) 3
drug administration schedule (3) 3
hematology, oncology and palliative medicine (3) 3
induction chemotherapy (3) 3
intensive chemotherapy (3) 3
leukemia, myeloid - drug therapy (3) 3
postremission (3) 3
postremission chemotherapy (3) 3
prospective studies (3) 3
recurrence (3) 3
young adult (3) 3
1st remission (2) 2
acute leukemia (2) 2
acute myeloblastic-leukemia (2) 2
adult patients (2) 2
allogeneic hematopoietic stem cell transplantation (2) 2
amsacrine - administration & dosage (2) 2
autologous stem cell transplantation (2) 2
autologous transplantation (2) 2
cebpa (2) 2
chromosome aberrations (2) 2
chromosomes (2) 2
clinical trials as topic (2) 2
combined modality therapy (2) 2
consolidation (2) 2
consolidation chemotherapy (2) 2
cytarabine (2) 2
daunorubicin (2) 2
daunorubicin - administration & dosage (2) 2
elderly (2) 2
elderly-patients (2) 2
etoposide - administration & dosage (2) 2
flt3-itd (2) 2
fms-like tyrosine kinase 3 - genetics (2) 2
granulocyte colony-stimulating factor - administration & dosage (2) 2
granulocyte colony-stimulating factor - adverse effects (2) 2
high-dose arabinoside (2) 2
immunology (2) 2
induction (2) 2
kaplan-meier estimate (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification
by Komanduri, Krishna V and Levine, Ross L
Annual review of medicine, ISSN 0066-4219, 1/2016, Volume 67, Issue 1, pp. 59 - 72
somatic mutation profiling | next-generation sequencing | induction chemotherapy | graft-versus-leukemia | postremission therapy | allogeneic hematopoietic stem cell transplantation | Graft-versus-leukemia | Somatic mutation profiling | Induction chemotherapy | Allogeneic hematopoietic stem cell transplantation | Next-generation sequencing | Postremission therapy | Prognosis | Risk Assessment | Humans | Risk Factors | Hematopoietic Stem Cell Transplantation | Induction Chemotherapy | Consolidation Chemotherapy | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Chromosome Aberrations | Mutation | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Chemotherapy | Medical diagnosis | Chromosomes | Leukemia | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial
by Schlenk, R.F and Benner, A and Hartmann, F and del Valle, F and Weber, C and Pralle, H and Fischer, J.Th and Gunzer, U and Pezzutto, A and Weber, W and Grimminger, W and Preiß, J and Hensel, M and Fröhling, S and Döhner, K and Haas, R and Döhner, H and AMLSG ULM and AML Study Group Ulm (AMLSG ULM) and for the AML Study Group Ulm (AMLSG ULM)
Leukemia, ISSN 0887-6924, 08/2003, Volume 17, Issue 8, pp. 1521 - 1528
Acute myeloid leukemia | Risk-adapted postremission therapy | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Acute Disease | Risk Assessment | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Stem Cell Transplantation - methods | Algorithms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Adult | Female | Remission Induction - methods | Cytogenetic Analysis | Leukemia, Myeloid - mortality | Stem Cell Transplantation - mortality | Leukemia, Myeloid - therapy | Leukemia, Myeloid - diagnosis | Mitoxantrone - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission
by Eto, Tetsuya and Takase, Ken and Miyamoto, Toshihiro and Ohno, Yuju and Kamimura, Tomohiko and Nagafuji, Koji and Takamatsu, Yasushi and Teshima, Takanori and Gondo, Hisashi and Taniguchi, Shuichi and Akashi, Koichi and Harada, Mine
International journal of hematology, ISSN 0925-5710, 8/2013, Volume 98, Issue 2, pp. 186 - 196
G-CSF combined conditioning regimen | Acute myelogenous leukemia | Autologous peripheral blood stem cell transplantation | Medicine & Public Health | Hematology | Oncology | First complete remission | Postremission therapy | Life Sciences & Biomedicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Autografts | Follow-Up Studies | Humans | Middle Aged | Etoposide - administration & dosage | Male | Survival Rate | Busulfan - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Agents, Phytogenic - administration & dosage | Adolescent | Myeloablative Agonists - administration & dosage | Adult | Female | Aged | Retrospective Studies | Transplantation Conditioning | Peripheral Blood Stem Cell Transplantation | Leukemia, Myeloid, Acute - therapy | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Granulocyte colony-stimulating factor | Stem cells | Transplantation | Macrophage colony stimulating factor | Hematopoietic stem cells | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
by Sanne Lugthart and Stefan Gröschel and H. Berna Beverloo and Sabine Kayser and Peter J.M. Valk and Shama Lydia van Zelderen-Bhola and Gert Jan Ossenkoppele and Edo Vellenga and Eva van den Berg-de Ruiter and Urs Schanz and Gregor Verhoef and Peter Vandenberghe and Augustin Ferrant and Claus-Henning Köhne and Michael Pfreundschuh and Heinz A. Horst and Elisabeth Koller and Marie von Lilienfeld-Toal and Martin Bentz and Arnold Ganser and Brigitte Schlegelberger and Martine Jotterand and Jürgen Krauter and Thomas Pabst and Matthias Theobald and Richard F. Schlenk and Ruud Delwel and Konstanze Döhner and Bob Löwenberg and Hartmut Döhner
Journal of clinical oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 24, pp. 3890 - 3898
CYTOGENETIC ABNORMALITIES | AML | ADULT PATIENTS | POSTREMISSION THERAPY | COLONY-STIMULATING FACTOR | BONE-MARROW-TRANSPLANTATION | NORMAL-TISSUES | ELDERLY-PATIENTS | EXPRESSION | UMCG Approved | ACUTE MYELOGENOUS LEUKEMIAS | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Multivariate Analysis | Predictive Value of Tests | Translocation, Genetic | Prognosis | Humans | Leukemia, Myeloid, Acute - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Neoplasm Proteins - metabolism | Chromosome Inversion | Proto-Oncogenes | Chromosomes, Human, Pair 3 | Karyotyping | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Odds Ratio | Leukemia, Myeloid, Acute - therapy | Monosomy | DNA-Binding Proteins | Leukemia, Myeloid, Acute - pathology | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Treatment Outcome | Clinical Trials as Topic | Cell Adhesion Molecules - metabolism | Remission Induction | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Chromosome Aberrations | Aged | Transcription Factors | Mutation | Genes, ras | MDS1 and EVI1 Complex Locus Protein | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations
by Heidrich, Katharina and Thiede, C and Schäfer-Eckart, K and Schmitz, N and Aulitzky, W.E and Krämer, A and Rösler, W and Hänel, M and Einsele, H and Baldus, C.D and Trappe, R.U and Stölzel, F and Middeke, J.M and Röllig, C and Taube, F and Kramer, M and Serve, H and Berdel, W.E and Ehninger, G and Bornhäuser, M and Schetelig, J and SAL and Study Alliance Leukemia (SAL)
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 11, pp. 2793 - 2798
CEBPA | NPM1 | Acute myeloid leukemia | FLT3-ITD | Hematopoietic stem cell transplantation | Postremission therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Prospective Studies | Follow-Up Studies | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Survival Rate | Remission Induction | Transplantation, Homologous | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Adolescent | Adult | Female | Biomarkers, Tumor - genetics | CCAAT-Enhancer-Binding Proteins - genetics | Mutation | Nuclear Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia
by Oran, Betül and Cortes, Jorge and Beitinjaneh, Amer and Chen, Hsiang-Chun and de Lima, Marcos and Patel, Keyur and Ravandi, Farhad and Wang, Xuemei and Brandt, Mark and Andersson, Borje S and Ciurea, Stefan and Santos, Fabio P and de Padua Silva, Leandro and Shpall, Elizabeth J and Champlin, Richard E and Kantarjian, Hagop and Borthakur, Gautam
Biology of blood and marrow transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 7, pp. 1218 - 1226
Hematology, Oncology and Palliative Medicine | AML | FLT3-ITD mutation | Allogeneic stem cell transplantation | Postremission therapy | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Recurrence | Prognosis | Consolidation Chemotherapy - methods | Consolidation Chemotherapy - mortality | Humans | Middle Aged | Male | Treatment Outcome | Tandem Repeat Sequences | Hematopoietic Stem Cell Transplantation - mortality | Remission Induction | Transplantation, Homologous | Leukemia, Myeloid, Acute - mortality | fms-Like Tyrosine Kinase 3 - genetics | Propensity Score | Alleles | Survival Analysis | Female | Aged | Hematopoietic Stem Cell Transplantation - methods | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Tyrosine | Chemotherapy | Analysis | Stem cells | Hematopoietic stem cells | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cost-effectiveness of postremission intensive therapy in patients with acute leukemia
by Yu, Y.-B and Gau, J.-P and You, J.-Y and Chern, H.-H and Chau, W.-K and Tzeng, C.-H and Ho, C.-H and Hsu, H.-C
Annals of oncology, ISSN 0923-7534, 03/2007, Volume 18, Issue 3, pp. 529 - 534
Acute myelogenous leukemia | High-dose arabinoside | Allogeneic stem-cell transplantation | Cost-effectiveness | Postremission therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Drug Costs | Follow-Up Studies | Precursor Cell Lymphoblastic Leukemia-Lymphoma - surgery | Humans | Middle Aged | Stem Cell Transplantation - economics | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Precursor Cell Lymphoblastic Leukemia-Lymphoma - economics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Arabinonucleosides - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - economics | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myeloid, Acute - surgery | Transplantation, Homologous - economics | Kaplan-Meier Estimate | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Health Care Costs | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Taiwan | Aged | Leukemia, Myeloid, Acute - economics | Transplantation, Autologous - economics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Postremission therapy for acute myeloid leukemia in the first remission
by Kim, Seung Tai and Jung, Chul Won and Lee, Jeeyun and Kwon, Jung Mi and Oh, Sung Young and Park, Byeong-Bae and Lee, Hyo Rak and Kim, Hyun Jung and Kim, Kihyun and Kim, Won Seog and Ahn, Jin Seok and Kang, Won Ki and Park, Keunchil
Leukemia & lymphoma, ISSN 1042-8194, 2007, Volume 48, Issue 5, pp. 937 - 943
AML | autologous HSCT | intensive chemotherapy | allogeneic | postremission therapy | Allogeneic | Intensive chemotherapy | Autologous HSCT | Postremission therapy | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Prognosis | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Remission Induction | Transplantation, Homologous | Disease-Free Survival | Time Factors | Adult | Female | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Leukemia, Myeloid, Acute - therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years
by Zhang, Ying and Zhang, Yimin and Chen, Qi and Tang, Gusheng and Zhang, Weiping and Yang, Jianmin and Wang, Jianmin and Hu, Xiaoxia
Annals of hematology, ISSN 0939-5555, 4/2019, Volume 98, Issue 4, pp. 997 - 1007
Allogeneic hematopoietic stem cell transplantation | Medicine & Public Health | Hematology | Oncology | Acute myeloid leukemia | Intermediate risk | Postremission therapy | NPM1 mut-neg CEBPA dm-neg FLT3-ITD neg | CEBPA | NPM1 | FLT3-ITD | Age Factors | Humans | Middle Aged | Risk Factors | Hematopoietic Stem Cell Transplantation | Male | Survival Rate | Leukemia, Myeloid, Acute - blood | Leukemia, Myeloid, Acute - mortality | Neoplasm, Residual | Disease-Free Survival | Allografts | Adolescent | Adult | Female | Neoplasm Proteins - blood | Retrospective Studies | Mutation | Neoplasm Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Chemotherapy | Transplantation | Chromosomes | Hematopoietic stem cells | Stem cells | Cancer | Medical prognosis | Leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT)
by Poire, Xavier and Labopin, Myriam and Cornelissen, Jan J and Volin, Liisa and Richard Espiga, Carlos and Veelken, J. Henik and Milpied, Noel and Cahn, Jean-Yves and Yacoub-Agha, Ibrahim and van Imhoff, Gustaaf W and Michallet, Mauricette and Michaux, Lucienne and Nagler, Arnon and Mohty, Mohamad
American journal of hematology, ISSN 0361-8609, 08/2015, Volume 90, Issue 8, pp. 719 - 724
REDUCED-INTENSITY | POSTREMISSION THERAPY | PROGNOSTIC IMPACT | POOR-PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | 1ST REMISSION | RANDOMIZED-TRIAL | STEM-CELL TRANSPLANTATION | MYELODYSPLASTIC SYNDROME | ACUTE MYELOBLASTIC-LEUKEMIA | Life Sciences & Biomedicine | Hematology | Science & Technology | Myeloablative Agonists - therapeutic use | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Transplantation, Homologous | Graft vs Host Disease - genetics | Graft vs Host Disease - mortality | Karyotyping | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Monosomy | Acute Disease | Leukemia, Myeloid, Acute - pathology | Europe | Hematopoietic Stem Cell Transplantation | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Survival Analysis | Aged | Chronic Disease | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Comparison of allogeneic stem cell transplantation, high‐dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia
by Tsimberidou, Apostolia‐Maria and Stavroyianni, Niki and Viniou, Nora and Papaioannou, Maria and Tiniakou, Maria and Marinakis, Theodoros and Skandali, Anastasia and Sakellari, Ioanna and Yataganas, Xenophon and Hellenic Cooperative Grp and Hellenic Cooperative Group and for the Hellenic Cooperative Group
Cancer, ISSN 0008-543X, 04/2003, Volume 97, Issue 7, pp. 1721 - 1731
high‐dose chemotherapy | de novo acute myelogenous leukemia (AML) | allogeneic stem cell transplantation | postremission therapy | autologous stem cell transplantation | De novo acute myelogenous leukemia (AML) | Allogeneic stem cell transplantation | High-dose chemotherapy | Autologous stem cell transplantation | Postremission therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Chemotherapy | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Bone marrow, stem cells transplantation. Graft versus host reaction | Pharmacology. Drug treatments | Transfusions. Complications. Transfusion reactions. Cell and gene therapy | Biological and medical sciences | Medical sciences | Antineoplastic agents | Drug Administration Schedule | Humans | Middle Aged | Male | Transplantation, Autologous | Treatment Outcome | Remission Induction | Cytarabine - administration & dosage | Transplantation, Homologous | Leukemia, Myeloid, Acute - mortality | Stem Cell Transplantation | Adolescent | Survival Analysis | Adult | Female | Transplantation Conditioning | Leukemia, Myeloid, Acute - therapy | Cancer regression | Evaluation | Transplantation | Cytarabine | Research | Stem cells | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights